Stratify Genomics

Stratify Genomics is a company specializing in cancer risk testing for the general population, headquartered in California, USA. Founded by an oncologist, the company has developed a low-cost next-generation sequencing method using patented chemical technology, aiming to enhance public awareness of cancer and other diseases so that patients and doctors can screen and treat more effectively. Stratify Genomics' flagship product, PGS, is a cancer detection tool that evaluates the genetic predisposition of men to prostate cancer and identifies individuals at higher risk of developing prostate cancer. PGS was created by Karim Kader, the director of urologic oncology at the University of California, San Diego, and is the first commercialized test from Stratify Genomics. The company's commercialization of next-generation sequencing methods can help small-scale tests save significant costs and time.